We observed a significant increase in GFAP levels in both AD and FTD patients compared to CTRL (mean ± SEM; AD, 236.70 ± 15.81 pg/mL vs. CTRL, 100.90 ± 9.42 pg/mL, Generalized Linear Model, padj < 0.001; FTD, 152.60 ± 16.32 pg/mL vs. CTRL, Generalized Linear Model, padj = 0.002) and in AD compared to FTD patients (AD vs. FTD, Generalized Linear Model, padj = 0.012) (Figure 2b). This evidence concerns the gene GFAP and Alzheimer disease.